Short-term colectomy is avoided in over half of regional patients failing medical therapy for acute severe ulcerative colitis with co-ordinated transfer and tertiary care.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
07 2020
Historique:
received: 15 04 2019
revised: 04 07 2019
accepted: 23 09 2019
pubmed: 8 10 2019
medline: 28 4 2021
entrez: 8 10 2019
Statut: ppublish

Résumé

Many patients presenting with an acute severe ulcerative colitis to a regional hospital are transferred to a metropolitan hospital for specialised care. This study aimed to evaluate the outcomes and characteristics of these patients. A retrospective observational cohort study was conducted to examine the 30-day colectomy rate using prospectively collected data on 69 consecutive index cases of acute severe ulcerative colitis transferred from regional hospitals to our metropolitan hospital meeting Truelove and Witts criteria. Those that avoided colectomy were followed out to 1 year to examine outcomes. The 30-day colectomy rate was 46.4% (32/69) in regional transfer patients. Rescue therapy was administered to 65% (45/69) of patients after transfer to our metropolitan hospital. Colectomy was avoided in 55% of these patients at 30 days. Colectomy free status was maintained in 78% (29/39) of these patients. Mortality was 0% at 30 days and 1 year. Over 50% of the patients failing therapy in a regional centre and requiring transfer avoided short term colectomy with co-ordinated referral for rescue therapy in a tertiary metropolitan inflammatory bowel disease unit. These patients would have ultimately required colectomy in their regional hospital without intervention.

Sections du résumé

BACKGROUND AND AIMS
Many patients presenting with an acute severe ulcerative colitis to a regional hospital are transferred to a metropolitan hospital for specialised care. This study aimed to evaluate the outcomes and characteristics of these patients.
METHOD
A retrospective observational cohort study was conducted to examine the 30-day colectomy rate using prospectively collected data on 69 consecutive index cases of acute severe ulcerative colitis transferred from regional hospitals to our metropolitan hospital meeting Truelove and Witts criteria. Those that avoided colectomy were followed out to 1 year to examine outcomes.
RESULTS
The 30-day colectomy rate was 46.4% (32/69) in regional transfer patients. Rescue therapy was administered to 65% (45/69) of patients after transfer to our metropolitan hospital. Colectomy was avoided in 55% of these patients at 30 days. Colectomy free status was maintained in 78% (29/39) of these patients. Mortality was 0% at 30 days and 1 year.
CONCLUSION
Over 50% of the patients failing therapy in a regional centre and requiring transfer avoided short term colectomy with co-ordinated referral for rescue therapy in a tertiary metropolitan inflammatory bowel disease unit. These patients would have ultimately required colectomy in their regional hospital without intervention.

Identifiants

pubmed: 31589361
doi: 10.1111/imj.14649
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

823-829

Informations de copyright

© 2019 Royal Australasian College of Physicians.

Références

Stenner JMCWP, Gould SR. Audit of the management of severe ulcerative colitis in a DGH. Gut 2001; 48 (Suppl 1): A87.
Physicians CEaEuatRCo. National Clinical Audit of Inpatient Care for Adults with Ulcerative Colitis UKInflammatory Bowel Disease (IBD) Audit. London, UK: Royal college of physicians; 2014; 1-60.
Nguyen GC, Laveist TA, Gearhart S et al. Racial and geographic variations in colectomy rates among hospitalized ulcerative colitis patients. Clin Gastroenterol Hepatol 2006; 4: 1507-13.
Kotwal S, Ranasinghe I, Brieger D et al. Long-term outcomes of patients with acute myocardial infarction presenting to regional and remote hospitals. Heart Lung Circ 2016; 25: 124-31.
Poulos M. Mortality from Asthma and COPD in Australia. Canberra: Australian Institute for Health and Welfare; 2014.
Chen TYT, Morrell S, Thomson W et al. Survival from breast, colon, lung, ovarian and rectal cancer by geographical remoteness in New South Wales, Australia, 2000-2008. Aust J. Rural Health 2015; 23: 49-56.
Australia Csac. Improving Inflammatory Bowel Disease Care Across Australia. Sydney: Price Waterhouse and Coopers; 2013; 1-53.
Statistics ABo. Belconnen ACT: National Regional Profile; 2010.
GlobeFeed.com. Distance Calculator and Driving Directions. Pune, India: Queensland; 2015.
Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6 discussion 16-9.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
Croft A, Walsh A, Doecke J et al. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013; 38: 294-302.
Team Rdc. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Programming; 2015.
Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
Dinesen LC, Walsh AJ, Protic MN et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010; 4: 431-7.
Farkas K, Molnar T, Szepes Z. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis. Expert Rev Gastroenterol Hepatol 2014; 8: 695-702.
Lindgren SC, Flood LM, Kilander AF et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5.

Auteurs

Desmond Patrick (D)

Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.

James D Doecke (JD)

CSIRO Health and Biosecurity/Australian E-Health Research Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

James Irwin (J)

Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Katherine Hanigan (K)

Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Lisa A Simms (LA)

Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Mariko Howlett (M)

Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

Graham L Radford-Smith (GL)

Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH